Progress in filovirus vaccine development: evaluating the potential for clinical use
- PMID: 21162622
- PMCID: PMC3398800
- DOI: 10.1586/erv.10.152
Progress in filovirus vaccine development: evaluating the potential for clinical use
Abstract
Marburg and Ebola viruses cause severe hemorrhagic fever in humans and nonhuman primates. Currently, there are no effective treatments and no licensed vaccines; although a number of vaccine platforms have proven successful in animal models. The ideal filovirus vaccine candidate should be able to provide rapid protection following a single immunization, have the potential to work postexposure and be cross-reactive or multivalent against all Marburg virus strains and all relevant Ebola virus species and strains. Currently, there are multiple platforms that have provided prophylactic protection in nonhuman primates, including DNA, recombinant adenovirus serotype 5, recombinant human parainfluenza virus 3 and virus-like particles. In addition, a single platform, recombinant vesicular stomatitis virus, has demonstrated both prophylactic and postexposure protection in nonhuman primates. These results demonstrate that achieving a vaccine that is protective against filoviruses is possible; the challenge now is to prove its safety and efficacy in order to obtain a vaccine that is ready for human use.
Figures
Similar articles
-
Prospects for immunisation against Marburg and Ebola viruses.Rev Med Virol. 2010 Nov;20(6):344-57. doi: 10.1002/rmv.661. Rev Med Virol. 2010. PMID: 20658513 Free PMC article. Review.
-
Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections.J Infect Dis. 2011 Nov;204 Suppl 3(Suppl 3):S1075-81. doi: 10.1093/infdis/jir349. J Infect Dis. 2011. PMID: 21987744 Free PMC article. Review.
-
Single-Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge.J Virol. 2018 Jan 17;92(3):e01190-17. doi: 10.1128/JVI.01190-17. Print 2018 Feb 1. J Virol. 2018. PMID: 29142131 Free PMC article.
-
Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus.J Virol. 2009 Jul;83(14):7296-304. doi: 10.1128/JVI.00561-09. Epub 2009 Apr 22. J Virol. 2009. PMID: 19386702 Free PMC article.
-
Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates.Hum Vaccin Immunother. 2019;15(10):2359-2377. doi: 10.1080/21645515.2019.1651140. Epub 2019 Oct 7. Hum Vaccin Immunother. 2019. PMID: 31589088 Free PMC article. Review.
Cited by
-
Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study.Lancet Infect Dis. 2013 Mar;13(3):238-50. doi: 10.1016/S1473-3099(12)70345-6. Epub 2013 Jan 29. Lancet Infect Dis. 2013. PMID: 23369412 Free PMC article. Clinical Trial.
-
Induction of ebolavirus cross-species immunity using retrovirus-like particles bearing the Ebola virus glycoprotein lacking the mucin-like domain.Virol J. 2012 Jan 25;9:32. doi: 10.1186/1743-422X-9-32. Virol J. 2012. PMID: 22273269 Free PMC article.
-
Protective efficacy of a bivalent recombinant vesicular stomatitis virus vaccine in the Syrian hamster model of lethal Ebola virus infection.J Infect Dis. 2011 Nov;204 Suppl 3(Suppl 3):S1090-7. doi: 10.1093/infdis/jir379. J Infect Dis. 2011. PMID: 21987746 Free PMC article.
-
A dead-end host: is there a way out? A position piece on the ebola virus outbreak by the international union of immunology societies.Front Immunol. 2014 Oct 27;5:562. doi: 10.3389/fimmu.2014.00562. eCollection 2014. Front Immunol. 2014. PMID: 25400640 Free PMC article. Review. No abstract available.
-
Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates.Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):1893-8. doi: 10.1073/pnas.1209591110. Epub 2013 Jan 14. Proc Natl Acad Sci U S A. 2013. PMID: 23319647 Free PMC article.
References
-
- Feldmann H, Geisbert T, Jahrling P, et al. Filoviridae. In: Fauquet CM, Mayo MA, Maniloff J, Desselberger U, Ball LA, editors. Virus Taxonomy: Eighth Report of the International Committee on the Taxonomy of Viruses. Elsevier; San Diego, CA, USA: 2005. pp. 645–653.
-
- Hoenen T, Groseth A, Falzarano D, Feldmann H. Ebola virus: unravelling pathogenesis to combat a deadly disease. Trends Mol Med. 2006;12(5):206–215. - PubMed
-
- Feldmann H, Jones S, Klenk HD, Schnittler HJ. Ebola virus: from discovery to vaccine. Nature Rev. 2003;3(8):677–685. - PubMed
-
- Sanchez A, Geisbert TW, Feldmann H. Filoviridae: Marburg and Ebola viruses. In: Knipe DM, Howley PM, Griffin DE, et al., editors. Fields’ Virology. Lippincott Williams and Wilkins; PA, USA: 2007. pp. 1409–1448.
-
- Bray M, Mahanty S. Ebola hemorrhagic fever and septic shock. J Infect Dis. 2003;188(11):1613–1617. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical